Gianluca Ballinari

Suggest Changes
Learn More
Antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with non-Hodgkin lymphoma (NHL) receiving moderately emetogenic chemotherapy (MEC) generally includes a serotonin-type 3(More)
9091 Background: Controlling CINV is integral to treatment success in cancer patients. Palonosetron HCl (PALO) is a potent 5-HT3 receptor antagonist with a longer t½ & a distinctly different receptor(More)
Preventing chemotherapy-induced nausea and vomiting (CINV) is integral to treatment success in patients with cancer. This analysis was undertaken to assess the relative efficacy and safety of(More)
BACKGROUND No clinical standard currently exists for the optimal management of nausea induced by emetogenic chemotherapy, 7particularly delayed nausea. OBJECTIVES To compare the effcacy and safety(More)
  • 1